Indian Pharma Industry Calls for Enhanced Support Amid USTR Special 301 Report Concerns
Pharmaceutical exporters urge government incentives for formulations to maintain global competitiveness despite minimal legal risks from USTR listing
India’s pharmaceutical sector faces scrutiny in the latest USTR Special 301 Report over intellectual property rights enforcement, particularly in formulations. Industry leaders stress compliance with WTO norms and advocate for policy measures to protect and promote the formulations segment, highlighting the sector’s v…